Concr

Biotechnology Research • London, England, United Kingdom • 1-10 Employees

Company overview

Headquarters	London, England, United Kingdom
Phone number	+4423650113974
Website	concr.co
NAICS	541714
Keywords	Biotechnology, Statistical Modelling, Machine Learning, Precision Medicine, Drug Development, Oncology Research
Founded	2018
Employees	1-10
Socials

Key Contacts at Concr

Irina Babina

Chief Executive Officer

Matthew Griffiths

Co-Founder

Matthew Foster

Co-Founder

Concr Email Formats

Concr uses 2 email formats. The most common is {first initial} (e.g., j@concr.co), used 50% of the time.

Format	Example	Percentage
{first initial}	j@concr.co	50%
{first name}	john@concr.co	50%

About Concr

Concr is a techbio company providing predictive modelling solutions to enhance confidence and foresight about therapeutic efficacy of existing and emerging cancer drugs. By accurately predicting response for individual patients and cohorts, we enable more efficacious and informative trials, thereby improving probability of success of novel cancer therapeutics. Our Farr-Sight® platform, built on decades of astrophysics research, models diverse data interactions to simulate human disease biology, enabling accurate predictions with minimal data. This is especially valuable in early-stage trials and rare cancers. Validated through collaborations with Roche, Step Pharma, The Institute of Cancer Research, The Christie NHS Foundation Trust, Durham University, and The University of Queensland, our solutions are trusted by researchers in industry, academia and healthcare. Concr’s investors include the University of Cambridge Enterprise, R42 Group, Oncology Ventures, Debiopharm, Cambridge Angels, Parkwalk Advisors, Deep Science Ventures and SyndicateRoom. The company has also received a grant from Innovate UK to trial Concr’s technology for improving treatment decision-making in clinic. The company’s HQ is in London, England, with a wholly owned subsidiary in Brisbane, Australia.

Concr revenue & valuation

Annual revenue	$684,440
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$2,200,000
Total funding	$1,500,000